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Murine leukemia viruses (MLVs) are among the simplest retroviruses. Prototypical gammaretroviruses encode only the three
polyproteins that will be used in the assembly of progeny virus particles. These are the Gag polyprotein, which is the structural
proteinofaretrovirusparticle,thePolprotein,comprisingthethreeretroviralenzymes—protease, which catalyzes thematuration
of the particle, reverse transcriptase, which copies the viral RNA into DNA upon infection of a new host cell, and integrase, which
inserts the DNA into the chromosomal DNA of the host cell, and the Env polyprotein, which induces the fusion of the viral
membrane with that of the new host cell, initiating infection. In general, a productive MLV infection has no obvious eﬀect upon
host cells. Although gammaretroviral structure and replication follow the same broad outlines as those of other retroviruses, we
point out a number of signiﬁcant diﬀerences between diﬀerent retroviral genera.
1.Introduction
A virus can be viewed as a rather regular, relatively simple
physical object. Alternatively, it can be seen as a living
organism, evolving in response to selective pressures. Both
views are correct! This paper will outline very brieﬂy some
of the characteristics of murine leukemia viruses (MLVs),
keeping both views in mind. We will try to point out the dis-
tinctive features of these retroviruses, which are often taken
as prototypes of the gammaretrovirus genus. (Retroviruses
include Spumaretroviruses (also known as “foamy viruses”)
and Orthoretroviruses; the latter are divided into six genera,
that is, alpha-, beta-, gamma-, delta-, epsilon-, and lenti-
retroviruses [1].)
MLVs have been studied for many years, beginning in
the 1950s, when it was realized that leukemia could be
transmittedtonewbornmicebyaﬁlterableagent[2–4].They
have provided many insights into the general phenomenon
of leukemogenesis. The MLV genome has also been used as
the starting material in the development of vectors for gene
therapy. Finally, MLVs have often been viewed as “model”
retroviruses. In fact, while they have been very useful in
answering questions about retroviruses and their hosts, there
aremanywaysinwhichgammaretrovirusesdiﬀerfromother
retroviruses:itshouldneverbeassumedthatagivenproperty
of one genus will hold for another.
The best-studied retrovirus is, of course, human immun-
odeﬁciency virus (HIV-1), which is a lentivirus. One striking
contrast between MLVs and HIV-1 is the relative simplicity
of MLVs. As discussed below, MLVs only encode the proteins
that will be assembled into the progeny virus particles,
whereas HIV-1 encodes six additional so-called “accessory”
proteins. Indeed, because of this distinction, HIV-1 has
frequently been called a “complex” retrovirus, in contrast to
the “simple” retroviruses such as MLV, the proper objects of
study of simple retrovirologists.
The two viruses also diﬀer in that HIV-1 can eﬃciently
infect nondividing cells, while MLV generally does not [5, 6]
(but see also [7, 8]). The ability of HIV-1 to infect nondivid-
ing cells is a critical element in its pathogenicity.
YetanothercardinaldiﬀerencebetweenMLVsandHIV-1
is that HIV-1-infected cells usually die rapidly (within a few
days at most) after infection. In contrast, at the cellular level
MLV infection seems almost completely benign: in general,
there are no detectable eﬀects of productive MLV infection
upon the growth, physiology, or morphology of the cells.
HIV-1 viremia is maintained in infected people by continual
infection of new cells, replacing the cells killed by infection.
We do not know how much infection is occurring in an
MLV-infected, viremic mouse, but since the virus does not
generally kill its host cells, the rate of new infections may be2 Advances in Virology
far lower than with HIV-1. It should be noted that the drugs
used in highly active antiretroviral therapy of HIV-infected
people act by blocking new infections; thus, it is possible
that analogous therapies would have only minimal eﬀects on
MLV viremia.
2.MLV: ThePhysicalObject
2.1. MLV Virions. The overall structures of virus particles
are probably very similar for all Orthoretroviridae. The
virus is pleomorphic, but roughly spherical, with a diameter
of ∼100–120nm [9]. It is released from the cell as an
“immature particle”, in which several thousand rod-shaped
Gag polyprotein molecules are arranged, in an incomplete
or imperfect hexameric lattice, as radii of the sphere (see
Figure 1). The sphere is bounded by a lipid bilayer derived
from the plasma membrane of the virus-producing cell. The
N-terminal matrix (MA) domains of the Gag molecules are
in contact with the lipid bilayer and their C-terminal nucleo-
capsid (NC) domains project into the interior of the particle,
presumably in contact with RNA. They are approximately
20nm long and only 2-3nm in diameter. The particle also
contains ∼1–300 Gag-Pol polyprotein molecules, in which
Gag is extended at its C-terminus by protease (PR), reverse
transcriptase (RT), and integrase (IN). Finally, trimers of the
envelope (Env) polyprotein span the membrane, with the
gp70surfaceglycoprotein(SU)ontheexterioroftheparticle,
complexed with the p15E transmembrane (TM) protein.
Roughly 2.5 × 104 nucleotides’ worth of RNA, representing
onlyafewpercentofthemassoftheparticle,arealsopresent
in the virion. Some cellular proteins are also packaged: this
has been documented in great detail in HIV-1 [10] but is also
true in MLV [11].
After the particle is released from the cell, it undergoes
maturation. PR cleaves Gag into four cleavage products, that
is,MA,p12,capsid(CA),andNC.ThePolmoietyofGag-Pol
is also cleaved to release free PR, RT, and IN proteins, and the
C-terminal16residuesofTM(the“Rpeptide”)areremoved,
producingthematureTMproteinp15E(insomepapers,this
shorter species is called p12E; the longer precursor has been
called either p15E or Pr15E). The cleavages in Gag cause a
major change in the overall architecture of the virion, with
CA molecules reassembling in the interior of the particle
into a polygonal structure, the “mature core” of the particle.
This new structure encloses a complex of the viral RNA with
NC protein; RT and IN are also presumed to be within this
structure.
2.2. The MLV Replication Cycle. As with all orthoretro-
viruses, infection is initiated by the binding of the SU
glycoprotein on the exterior of the mature, infectious virion
toareceptoronthesurfaceofthenewhostcell(seeFigure2).
This binding event triggers dramatic changes in Env, leading
to the release of the SU component and conformational
rearrangement of TM. The ultimate result is the fusion of the
viral membrane with the plasma membrane.
The fusion of the two membranes leads to the deposition
ofthecontentsofthevirioninthecytoplasmofthecell.Once
in the cytoplasm, the viral RNA is copied by the RT into a
LB MA P12 CA NC
Figure 1: Structure of an immature MLV particle. A segment
from a rotationally averaged cryoelectron microscopic image of a
single immature MLV particle is shown on the right. As indicated
on the left, the particle is bounded by a lipid bilayer (“LB”),
and the MA domain of Gag (pink) is associated with the inner
leaﬂet of the bilayer. Interior to the MA domain is a zone of
low density, presumably corresponding to the p12 domain. The
most conspicuous feature of the image is the “railroad tracks”,
representing the two domains within the CA domain (green),
followed by the NC domain (blue) with bound RNA. The Pol and
Envproteinsarenotvisibleinthisimage.Astheparticleis ∼100nm
in diameter and the Gag molecules are ∼20nm in length, there is a
region ∼60nm in diameter largely occupied by solvent in the center
of the particle. (Reproduced from [9]. Copyright 1998, National
Academy of Sciences, USA.)
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Figure 2:Theorthoretroviralreplicationcycle.Infectionisinitiated
when the mature, infectious virion binds to a receptor on the
surface of the new host cell. The Env protein of the virus induces
fusionbetweentheviralmembraneandthecellmembrane(Step1).
Within the cytoplasm, the mature core dissociates (Step 2) and
the dimeric viral RNA (shown in orange) is copied (Step 3) into
double-stranded DNA (shown in green). The DNA copy enters the
nucleus(probablywhenthenuclearmembranebreaksdownduring
mitosis) and is inserted into the chromosomal DNA of the cell
(Step 4). The DNA is transcribed and the RNA product is exported
from the nucleus (Step 5); within the cytoplasm, some molecules
will be translated into viral proteins, and others are destined for
encapsidation into progeny virus particles. The viral components
assemble into budding virions (Step 6), which are released from
the cell as immature particles (Step 7). Finally, PR cleaves the viral
proteins, converting immature particles into mature, infectious
virions (Step 8). It is possible that DNA synthesis actually occurs
within the mature core rather than after dissociation of the core as
shown here.Advances in Virology 3
single molecule of dsDNA. This DNA is somehow conveyed
into the nucleus, where the IN protein catalyzes its insertion
into chromosomal DNA.
Once the viral DNA is integrated into host DNA, it
is termed the “provirus”. It is transcribed and translated
by normal host-cell machinery. The encoded proteins are
traﬃcked to the plasma membrane, where they assemble
into progeny virus particles. The immature particles are
released from the cell with the help of the cellular “ESCRT”
machinery [23] and subsequently undergo maturation as the
PR in the virus cleaves the viral polyproteins. The particle is
notcapableofinitiating anewinfectionuntil maturationhas
taken place.
2.3. The MLV Genome. The RNA genome of MLV can be
divided into coding and noncoding regions and is shown
schematically in Figure 3.
2.3.1. Coding Regions. The only proteins encoded by the
MLV genome are the three polyproteins that will make up
the progeny virus particles: Gag, the structural protein of
the immature virus particle, Pol, comprising the PR, RT, and
IN enzymes, and Env, the SU and TM proteins that jointly
mediate the entry of an infectious virus particle into a new
host cell to initiate infection [18]. In some MLV isolates, an
alternativeformofGag,withanN-terminalextension,isalso
synthesized; this “glyco-Gag” is discussed below.
As in all orthoretroviruses, the three coding regions are
arranged, from 5  to 3 ,Gag:P ol:Env .TheP olproteinsare
initially synthesized together with Gag, in a large Gag-Pol
fusion polyprotein. Gag and Gag-Pol are both translated
from full-length viral RNA, identical in sequence to the
genomic RNA present in the virion. It seems likely that
the Gag-Pol polyprotein is incorporated into assembling
virions due to “coassembly” of its Gag moiety with Gag
polyprotein molecules. Successful replication of the virus
requires maintenance of an optimal ratio (on the order of
20:1) between the Gag and Gag-Pol proteins; indeed, no
detectable virus particles are formed in cells expressing only
Gag-Pol [24]. This may be because Gag-Pol is more than 3
times the mass of Gag, and thus, there may not be space
within the particles for very many Pol domains. This optimal
ratio is achieved by ﬁnely tuned translational suppression of
the termination codon at the end of the Gag coding region.
Remarkably, diﬀerent retroviruses use fundamentally
diﬀerent mechanisms of translational suppression. In the
gammaretroviruses such as MLV (and epsilonretroviruses, a
genus about which very little is known), Gag and Pol are in
the same reading frame, separated by a single termination
codon. MLV RNA contains a 57-base cis-acting signal
immediately 3  of the termination codon [25]. This signal
induces the insertion of glutamine (normally encoded by
CAG), rather than termination, in response to the UAG
termination codon in about 5% of the translation products;
the resulting product is extended by translation of the entire
Pol coding region [26]. Similar results are obtained when the
UAG is replaced by UGA or UAA [27,28].Thus,theseviruses
operate in essence by “mis-translation” of the termination
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Figure 3: The MLV genome. The viral RNA in Moloney MLV is
8332nt in length [18]. “R” sequence, 68nt in length, is identical at
both ends of the RNA. The 5  c o p yo fRi sf o l l o w e db yU 5s e q u e n c e s
and then by the PBS (nt 146–163). The long 5  untranslated region
in the RNA also includes the ψ packaging signal; contained within
this signal in some MLV isolates is the CUG codon at which glyco-
Gag translation is initiated (nt 357). The initiation codon for the
“normal”Gagproteinisatnt621.Thegag andpolcodingsequences
are in the same frame; they are separated by a UAG termination
codon, which in turn is followed immediately by a 57-base signal,
including an RNA pseudoknot, inducing the ineﬃcient translation
of the UAG as glutamine. The Env protein is translated from a
spliced mRNA. The polypurine tract (PPT, nt 7803–7815) is the
primer for +-strand DNA synthesis and is followed by the U3 and R
regions. U3 (nt 7816–8264) is placed at the 5  end of the DNA copy
of the genome synthesized during infection; it contains promoter
and enhancer sequences governing the initiation of transcription at
the beginning of R.
codon as a sense codon. In contrast, in all other genera,
the suppression occurs before the ribosomes encounter the
termination codon and is completely independent of this
codon. In these viruses, Pol is encoded in the “−1” frame
relative to Gag. A signal in these viral RNAs before the
end of the Gag coding region induces a fraction of the
ribosomes to advance two, rather than three bases at a
speciﬁc codon so that translation by this subset of ribosomes
is shifted from the Gag frame to the Pol frame [29, 30]. (In
some retroviruses, there are two frameshifting events, one
extending Gag to produce Gag-PR and the second extending
Gag-PR to yield Gag-PR-RT-IN.) A detailed discussion of
translational suppression in retroviruses may be found in
Hatﬁeld et al. [31].
The Env protein of MLV, like that of other orthoretro-
viruses, is translated from a singly spliced mRNA. There is an
overlap of 58 bases between the end of the Pol coding region
and the beginning of the Env coding region.
2.3.2. Noncoding Regions. Like the RNAs of all orthoretro-
viruses, MLV RNA also contains a set of cis-acting signals
that are essential for its function as a viral genome. These
include the “primer binding site” (PBS), the polypurine tract
(PPT), the “packaging signal” or ψ, sequences required for
insertion, by IN, of the DNA form of the viral genome into
cellular DNA, and the promoter and enhancer sequences
within the LTR.
The PBS is an 18-base stretch that is complementary
to the last 18 bases of a cellular tRNA molecule. In MLVs,
this is usually tRNAPro, but MLVs using tRNAGln have also
been found. Within the virion, the tRNA is hybridized to
the viral RNA; when the virus enters a new host cell, the
tRNA serves as the primer for reverse transcription. The
PBS is located ∼145 bases from the 5  end of the RNA and
∼460 bases 5  of the beginning of the Gag coding region.4 Advances in Virology
The ﬁrst deoxynucleotide to be added to the tRNA during
reverse transcription is determined by pairing with the base
immediately 5  of the PBS, and this base is the 5  terminus
of the ﬁrst (minus) strand in the ﬁnal DNA product. In other
words, this site is the “right” end of the ﬁnal double-stranded
D N Ap r o d u c to fr e v e r s et r a n s c r i p t i o n .
In general, during reverse transcription the RNA is
copied by the polymerase activity of RT and is progressively
degraded, shortly after being copied, by the RNase H
a c t i v i t yo fR T .H o w e v e r ,a ne x c e p t i o n a ls t r e t c ho f∼15
purines near the 3  e n do fr e t r o v i r a lR N A s( t h eP P T )i s
speciﬁcally resistant to this degradation. Having survived
reverse transcription, this fragment of the viral RNA is the
primer for synthesis of the second (plus) strand of DNA. The
base immediately 3  of the PPT encodes the ﬁrst base of the
plus strand of the DNA copy, that is, the 5  end of the plus
strand or “left” end of the double-stranded DNA.
ThesesequencesatthetwoendsoftheﬁnalDNAproduct
are, of course, the sequences joined by IN to host-cell
chromosomal DNA during the integration reaction. The two
ends form an inverted repeat (reviewed in [32]). In Moloney
MLV, the sequence of the “plus” strand at the right edge
is 5  GGGGTCTTTCA 3 , while that at the left edge is 5 
TGAAAGACCCC 3 . The bases at the 3  ends of the plus
strand on the right edge, and the 5  end of the left edge, are
joined to cellular DNA, but it is the internal bases in these
sequences that are essential for IN recognition [33, 34].
All orthoretroviral genomic RNAs are, as noted above,
mRNAs. They resemble cellular mRNAs in having a 5 
cap and 3  poly (A) tail. In fact, under certain conditions,
retrovirus particles can encapsidate cellular mRNAs [35].
Thus, the viral RNAs are evidently in competition with
cellular mRNAs for incorporation into the virions. Intact
retroviral RNAs are selectively incorporated because they
contain a “packaging signal”, giving them an advantage in
this competition.
Recent structural studies have shed considerable light on
the nature of the packaging signal in Moloney MLV RNA
(see Figure 4)[ 20, 36]. Brieﬂy, in all orthoretroviruses, the
viral RNA is actually packaged in dimeric form, with two
molecules of the viral RNA linked by a limited number of
intermolecularbasepairs. Theprimary location of thesebase
pairs is in the “leader”, between the PBS and the beginning
of the Gag coding sequence. MLV RNA, like that of all
gammaretroviruses, contains a pair of stem loops in this
region with the sequence GACG in the loop [37]. Both
NMR and chemical-probing data show that when MLV RNA
dimerizes, the “CG” within each of these GACG’s pairs with
the CG in the other monomer (note that “CG” is a 2-base
palindrome,theshortestpossiblepalindromicsequence)[38,
39]. Further, two other stem loops in the monomers open
outandpairintermolecularly. Mostinterestingly, this change
entails a shift in register so that some of the bases which
are paired in intramolecular structures in the monomers
become unpaired in the dimers. These bases include two
copies of the motif UCUG-UPu-UCUG. Several kinds of
experiments [20] show that this motif is essential for high-
aﬃnity binding by recombinant MLV Gag protein, that
these bases are occupied by NC protein within mature MLV
particles, and that they are crucial to selective packaging.
These results explain why dimers, but not monomers, of
viral RNA are selectively packaged and also establish that the
speciﬁc, high-aﬃnity binding of Gag to ψ is responsible for
selective packaging.
During reverse transcription, sequences from near the
3  end of the viral RNA (“U3” sequences) are placed at
the 5  end, as well as near the 3  end, of the viral DNA.
(Conversely, U5 sequences, from near the 5  end of the
RNA, are placed at the 3  e n da sw e l la sn e a rt h e5  
end of the DNA.) Following integration of the viral DNA,
the U3 sequences at the 5  end constitute the promoter
and enhancers driving the transcription, by Pol II, of the
integrated DNA. U3 sequences include a dense collection
of transcription factor-binding sites; they were used in the
experiments that originally demonstrated the existence of
enhancers [40] and play a major role in determining the
tissue tropism and pathogenicity of the virus (reviewed in
[41]). The placement of the U3 sequences, which are internal
in viral RNA, upstream of the transcriptional start site in the
DNA is an elegant solution to the problem of how to ensure
that the viral sequences will lie 3  of a promoter, as required
for Pol II transcription.
2.4. MLV Proteins
2.4.1. Gag. In essence, the orthoretrovirus particle is con-
structed by assembly of Gag protein molecules. All
orthoretroviral Gag proteins contain at least three domains,
which will give rise to three distinct proteins in the mature
virus. The MA domain at the N-terminus of Gag is respon-
sible for targeting the protein to the plasma membrane of
the virus-producing cell. In MLV, as in most retroviruses, the
N-terminus of Gag is modiﬁed by the 14-carbon saturated
fatty acid, myristic acid [42]; this modiﬁcation is important
for the plasma-membrane association of Gag [43]. The CA
domain is the locus of most, if not all, of the interactions
between Gag molecules leading to the assembly of the imma-
turevirion.AftertheCAmoleculesarereleasedfromtheGag
polyproteinbyPR,theyreassembleintothematurecore.The
NC domain plays a predominant role in the interactions of
Gag proteins with RNAs, and free NC protein is an essential
cofactor in reverse transcription during infection. In general,
there is considerable structural conservation between the
Gag proteins in diﬀerent orthoretroviral genera, despite the
almost complete lack of conservation of primary sequences.
MLV Gag diﬀe r si nt w oi m p o r t a n tr e s p e c t sf r o mt h e
canonical MA-CA-NC Gag structure (see Figure 5). First,
it contains an additional domain, called p12, situated
betweenMAandCA.p12containsthePro-Pro-Pro-Tyr“late
domain” of MLV [44]; this motif interacts with an Nedd4-
like ubiquitin ligase to promote the release of the assembled
virion from the host cell [45]. p12 also participates in the
infection process, but these additional functions are not well
understood. It is part of the “preintegration complex”, a
collection of proteins from the infecting virus particle that
accompany the newly synthesized viral DNA into the cell
nucleus [46], and some mutations in p12 interfere with
proper integration [47, 48]. Surprisingly, there are regionsAdvances in Virology 5
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Figure 4: The Moloney MLV dimerization/packaging signal. The ﬁgure shows the secondary structure of the 170-base “minimal
dimerization active sequence” (nt 205–374) [19] in both monomeric and dimeric forms. Two palindromic sequences, “PAL1” (green) and
“PAL2” (red), are contained within stem loops in the monomer but open out and pair intermolecularly in the dimer. The two monomers
are also connected in the dimer by base pairing between the “CG” moieties in the “GACG” loops of a pair of stem loops (“SL1” and “SL2”,
orange). The RNA also contains two motifs with the sequence UCUG-UPu-UCUG (blue boxes); these are partially or fully base-paired in
the monomer but become unpaired as a result of the RNA rearrangements accompanying the intermolecular base pairing of PAL1 and PAL2.
These bases are a crucial element in ψ, as replacement of the four UCUG sequences with UCUA prevents selective packaging of the viral
RNA; the exposure of these bases in dimers, but not monomers, presumably explains the selective packaging of dimeric RNA [20]. (Figure
reproduced from Trends in Biochemical Sciences, Copyright 2011, with permission from Elsevier [21].)
withinp12inwhichsequencechangesseemtohavenomajor
eﬀect on viral function [49, 50], and the maturation cleavage
between MA and p12, unlike the other cleavages, is not
absolutely essential for viral infectivity [51]. It is extremely
proline-rich (18 of its 84 residues (21%) are prolines), and
it has been described as “unstructured” on the basis of
NMR data [52]. However, recombinant MLV Gag protein
is an extended rod in solution, and the prolines in the p12
domain contribute to its rigidity (Datta et al., manuscript
in preparation). It seems likely that this domain in Gag can
assume any of a number of rigid conformations containing
short polyproline helices.
Second, some, but not all, MLV isolates encode an
alternative form of the Gag polyprotein, called “glyco-Gag”
orgPr80Gag.Thisproteindiﬀersinsequencefrom“standard”
Gag in that it is extended N-terminally. Synthesis of glyco-
Gag is initiated at a CUG codon in a favorable context for
MA p12 CA NC
Figure 5:MLVGagprotein.TheMLVGagproteinismodiﬁedatits
N-terminus by the 14-carbon fatty acid myristic acid. It is cleaved
during virus maturation into MA, p12, CA, and NC; most of the
NC molecules are also cleaved 4 residues before their C-terminus.
translation initiation, 264 bases 5  of the normal Gag AUG
initiation codon [53]. The N-terminal extension includes a
signal sequence so that this protein (unlike standard Gag)
is synthesized in the rough endoplasmic reticulum and
processed in the Golgi apparatus. Relatively little glyco-Gag
is incorporated into virions [54]. Because of a sequence
polymorphism at the site of the CUG initiator, XMRV does
not encode glyco-Gag.6 Advances in Virology
The functional signiﬁcance of glyco-Gag is still not clear.
Early studies showed that it is not essential for replication
of MLV in cell culture, but is needed for eﬃcient replication
and pathogenicity in mice [55, 56]. It was recently reported
thatthecorrectassemblyofstandardMLVGagintospherical
immature particles in cell cultures is impaired in the absence
of glyco-Gag [57]; new data indicates that the presence of
glyco-Gag directs virion assembly to lipid rafts and that this
function involves the cellular La protein [58]. Remarkably,
glyco-Gag can also complement Nef deletions in HIV-1
[59].
MLV Gag is also unusual among orthoretroviral Gags in
that its NC domain only contains a single zinc ﬁnger rather
than two as in most genera. The zinc-coordinating residues
have the spacing C-X2-C-X4-H-X4-C, as in all orthoretrovi-
ral NC proteins. This 14-residue motif plays a critical role
in the selective packaging of genomic RNA, among other
functions [60, 61]. The last 4 residues of NC are removed
from the majority of Gag molecules, as they are from Gag-
Pol molecules, during virus maturation [26, 62].
2.4.2. Pol. As noted above, the products of cleavage of the
Gag-PolpolyproteinincludePR,RT,andIN.PRcatalyzesthe
cleavages leading to virus maturation; like all retroviral PRs,
it is an aspartic protease which is only active as a dimer [63,
64].
RT synthesizes the DNA copy of the viral genome during
infection. This function involves three enzymatic activities:
RNA-templated DNA synthesis, DNA-templated DNA syn-
thesis, and degradation of the RNA strand in an RNA:DNA
hybrid, eliminating the RNA template immediately after
synthesis of the complementary DNA strand. MLV RT is
apparently active as a monomeric protein [65, 66] unlike the
RTenzymesofalpharetrovirusesandlentiretroviruses,which
are both heterodimers [67].
Retroviral IN enzymes possess two catalytic activities: “3 
end processing”, in which IN removes two nucleotides from
the 3  end of each strand of the DNA to be integrated, and
“strand transfer”, in which the new 3  ends are inserted into
chromosomal DNA in the new host cell [32]. MLV IN has
not been characterized in detail but is presumed to function
as a tetramer [68, 69].
2.4.3. Env. As with all orthoretroviruses, the MLV Env gene
product is synthesized in the rough endoplasmic reticulum
and glycosylated in the Golgi apparatus. It is also cleaved in
the Golgi by a cellular furin-like protease into two fragments,
the large, N-terminal surface glycoprotein (gp70SU) and the
C-terminal transmembrane protein p15ETM.At r i m e ro f
these heterodimeric SU-TM complexes is then traﬃcked
to the cell surface. As mentioned above, it undergoes an
additional cleavage during virus maturation: PR removes the
C-terminal 16 residues, also known as the “R peptide”, from
the cytoplasmic tail of the TM protein [62, 70]. This matu-
ration cleavage of TM is found in the gammaretroviruses, in
Mason-Pﬁzer monkey virus, a betaretrovirus [71, 72], and in
thelentivirusequineinfectiousanemiavirus[73],butnot,as
far as is known, in other retroviruses.
MLV Env is depicted schematically in Figure 6.M a t u r e
SU of Moloney MLV is 435 residues in length, while TM is
180 residues. In turn, SU contains an N-terminal “receptor-
binding domain” (RBD) of ∼240 residues, a short, proline-
rich “hinge” region, and a highly conserved C-terminal
domain[74].TheRBDconsistsofanantiparallelβ-sandwich
projecting “up” from the surface of the virion, and a
highly variable region resting atop this scaﬀold. Both ends
of the RBD contribute to this β-sandwich [75]. Sequence
alignments and analysis of chimeric SU proteins show that
thevariablesequenceswithintheRBDmakespeciﬁccontacts
with cell-surface receptors. Among the conserved features of
SU are a histidine residue near the extreme N-terminus and
a CXXC motif in the C-terminal portion of SU. TM protein
begins with a very hydrophobic stretch, the “fusion peptide”.
As t r e t c hb e t w e e nT Mr e s i d u e s4 3a n d7 8( i nM o l o n e yM L V )
has a 4-3 repeating pattern of hydrophobic residues that
forms a coiled coil. TM also contains a CX6CC motif; in the
virus particle, there is a disulﬁde bond joining SU, via one of
the cysteines in the CXXC, to TM, via the last cysteine in the
CX6CC [76–78].
The function of the Env complex is to induce fusion
between the membrane surrounding the virus particle and
the membrane of a new host cell. As in all orthoretroviruses,
the cleavage between SU and TM is absolutely required for
Env function [79]. Presumably, this is essential because it
places the fusion peptide at the N-terminus of TM rather
than in the interior of the Env polyprotein. The removal
of the R peptide from the C-terminus of Prp15E during
virus maturation is also necessary for the fusogenicity of
Env [80, 81]. It seems likely that fusogenic activity would be
harmful to the virus-producing cell and that the R peptide is
a “safety catch” suppressing this activity until the virus has
left the cell. The mechanism by which the R peptide inhibits
fusion is not known, but, remarkably, it has the same eﬀect
when joined to the inﬂuenza HA protein [82].
The fusion between the two membranes by the mature
Env complex is the end result of an amazing cascade
of events. Brieﬂy, binding to the receptor on the plasma
membrane induces a conformational change in the RBD.
This change is propagated in SU, resulting in the ionization
of the one free thiol in its CXXC motif [83]. (The conserved
histidine near the N-terminus of SU, which is essential
for Env function, may catalyze this ionization [84].) The
ionized sulfur then attacks the neighboring cysteine, and
the disulﬁde linkage between SU and TM is replaced by an
intra-SU bond between these two cysteines. Breaking the
SU-TM bond releases SU from the Env complex, exposing
the fusion peptide at the N-terminus of TM. The fusion
peptide inserts into the target membrane; this is followed
by a major conformational change in TM, in which a C-
terminal heptad repeat-like sequence in the TM ectodomain
folds against the N-terminal heptad repeat [76]. This shift to
a hairpin conﬁguration brings the two membranes into very
close apposition; this ﬁnally results in the fusion of the two
membranes.
FurtherstudiesmakeitclearthatRBDfunctionsnotonly
to bind a receptor on the target cell, but also to prevent
the conformational change in TM, leading to membraneAdvances in Virology 7
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Figure 6: MLV Env protein. MLV Env protein consists of a complex
between gp70SU and p15E
TM. The cartoon shows that gp70 has two
domains, RBD at its N-terminus and “C-term” at its C-terminus,
separated by a variable, proline-rich linker. P15E contains, from
N- to C-terminus, the fusion peptide (FP), an N-terminal helical
domain (helix A), a short C-terminal helical domain (helix B), and
a C-terminal domain (light pink) which spans the viral membrane
(yellow). Gp70 is exclusively external to the virus and is connected
to p15E by a disulﬁde linkage between one of the two cysteines in a
CXXC motif within its C-terminal domain and the last cysteine in a
CX6CC motif in p15E.
fusion, from occurring prematurely, that is, before contact
of the virus with the receptor [85, 86]. In fact, under special
circumstances infection can occur “in trans”, that is, when a
soluble RBD binds a cell-surface receptor in proximity to the
virion[87]. This activity of the MLV Env complex has special
consequences for the “MCF” class of MLVs. These “mink cell
focus-inducing” or “polytropic” MLVs arise in mice that are
viremic for ecotropic MLVs, and are recombinants in which
the ecotropic RBD has been replaced by an RBD from an
endogenous MLV genome [88–90]. This substitution gives
the MCF a diﬀerent receptor speciﬁcity from that of its
ecotropic parent [13–15, 91]. The complex of the ecotropic
SU protein with the ecotropic receptor on target cells (as in
the viremic mice) has been shown to facilitate infection of
the cells by MCF virions [92].
Remarkably, TM protein performs yet another func-
tion for MLV. Immediately proximal to the CX6CC motif
discussed above is a 20-residue stretch which has potent
immunosuppressive activity; this activity is crucial in MLV
infections in mice [93, 94].
As indicated above, MLVs are polymorphic with respect
to their use of cell-surface receptors. In general, when a cell is
productively infected with an MLV, the viral Env protein sat-
urates the receptors that it would use for infection, rendering
thecellalmostcompletelyresistanttosuperinfectionbyvirus
particles that use the same receptor. This resistance makes it
possibletogroupMLVisolatesintofamiliessharingcommon
receptors. “Interference” measurements of this kind showed
that NIH/3T3 mouse cells have four distinct cell-surface
molecules used as receptors by diﬀerent MLVs, as indicated
inTable1[91,95].Thispolymorphismisconsideredindetail
in a comprehensive review [96], and is discussed in other
articles in this series. It is notable that all receptors used
by MLVs contain multiple membrane-spanning domains,
unliketheknownreceptorsformostotherorthoretroviruses.
3.MLV: TheOrganism
3.1. Assays for Infectious MLV. Quantitative virology is
virtually impossible without a reliable infectivity assay [97].
Since MLVs generally have no obvious eﬀect on the cells
they infect, the opportunities for developing a “plaque” or
“focus” assay have been very limited. Two such assays have
beendevised,eachexploitingaspeciﬁccelllinewithaunique
response to MLV infection.
One of these is the “UV-XC” test [98]. XC cells, derived
from a rat tumor induced by Rous sarcoma virus, undergo
rapid syncytium formation when they come into contact
with cells producing ecotropic MLV. This property was used
to develop an “indirect” plaque assay: a plate of permissive
cells is ﬁrst infected with the virus, and the virus is allowed
to spread in these cells for 5–7 days. At the end of this period,
the cells have grown into a conﬂuent monolayer, and the
plate contains invisible “foci” of MLV-producing cells. Each
focus has arisen by the localized spread of virus from a single
cell, infected by a virus in the inoculum, to neighboring
cells;severalroundsofreplicationcanoccurduringtheassay.
This monolayer is then killed by UV-irradiation and overlaid
with XC cells. A day later, the XC cells have replaced the
original cells; they are ﬁxed and stained, and “plaques”, that
is, localized regions of syncytia, are counted. One particular
advantage of this assay is that it can be used to measure
the infectivity of any ecotropic MLV on any cells; thus, for
example, comparing the titer of a single virus preparation on
NIH/3T3 cells and Balb/3T3 cells tells one whether the virus
is N-tropic, B-tropic, or NB-tropic. On the other hand, the
factthat it only detects ecotropic MLVs is a serious limitation
of the UV-XC test.
The other quantitative assay for replication-competent
MLV is the S+L− assay [99]. S+L− cells are speciﬁc cell lines
transformed by Moloney sarcoma virus. When these cells
are superinfected by an MLV, they become much rounder
and more refractile (this may reﬂect “hypertransformation”,
perhaps due to reinfection of the cells with additional copies
of Moloney sarcoma virus after it has been rescued by the
MLV). In this assay, S+L− cells are infected and allowed
to grow for ∼5 days; “foci” of rounded cells, which stand
out against the conﬂuent monolayer of uninfected S+L−
cells, are then scored under a low-power microscope. This
assay has the advantage that it will detect any replication-
competent MLV, not just members of a speciﬁc class.8 Advances in Virology
Table 1: MLV receptors on NIH/3T3 mouse cells.
Virus class Example Receptor Reference
Ecotropic Moloney mCAT1 [12]
MLV
Polytropic MCF247 XPR1 [13–15]
Amphotropic 1504A SLC20A2 [16, 17]
SLC20A1
10A1 10A1 or [16, 17]
SLC20A2
The table lists the receptors for MLVs found on NIH/3T3 mouse cells. The
diversity of MLV receptors is discussed in more detail in other articles of this
series.
However, it is extremely time consuming. It can also be
diﬃcult to distinguish the foci from random irregularities in
the cell monolayer, so scoring the assay requires considerable
skill and involves some judgment.
For many, but not all, kinds of experiments, replication-
defective “reporter” viruses rescued by MLV can be assayed
in lieu of assaying the MLV itself. The reporter viruses
originally used in this way were acute transforming viruses;
for example, MLVs were grouped into interference families
by measuring the ability of Harvey MSV pseudotypes to
transform MLV-infected cells [91, 95]. More recently, of
course, MLV-derived vectors expressing a variety of genes,
such as luciferase, β-galactosidase, and green ﬂuorescent
protein, have been constructed for use as reporter viruses
(e.g., [100]).
Cell lines have also been developed in which a reporter
gene is only expressed following replication in the cell of
an MLV. These cells contain an MLV-derived vector which
carries a reporter gene in reverse orientation; the reporter
gene is interrupted by an intron in the forward orientation.
Transcription and splicing yields an RNA in the cell with an
uninterrupted, negative-sense copy of the reporter gene; if
this RNA is rescued by an MLV, it can be copied into DNA,
ﬁnally producing an intact reporter gene whose expression
can be measured (Aloia et al., manuscript in preparation,
but see [101]). This assay has the special advantage that it
can be performed by cocultivation of the assay cells with cells
producing the virus to be assayed, as well as by infection of
the assay cells with cell-free virus.
3.2. Endogenous MLVs. At least 100 times over the course of
evolution, MLVs have infected cells of the mouse germline.
Once the viral DNA has integrated into the germline DNA, it
is passed from parents to oﬀspring just like any other mouse
gene. The biology of these “endogenous” MLVs and their
eﬀects on their hosts are quite complex and are considered
in other articles in this series.
3.3. Resistance to MLV. While MLVs are generally benign
at the cellular level, they do induce both lymphomas and
neurological diseases in mice. Mice have evolved a number
of resistance mechanisms that inhibit the growth of MLVs;
MLVs have, in turn, developed strategies for evading these
defense mechanisms.
3.3.1. Superinfection Interference. Two genes inducing strong
resistance to speciﬁc envelope classes of MLV have been
described: Fv-4 and Rmcf [102, 103]. Both of these genes
have been found to function by superinfection interference:
in other words, the genes encode glycoproteins which
bind MLV receptors, rendering the receptors unavailable
for incoming viruses. Fv-4 blocks the ecotropic receptor,
mCAT1, whereas Rmcf blocks the MCF receptor XPR1. It
seems reasonable to imagine that these genes were originally
introduced into the mouse genome as the Env genes of
endogenous MLVs.
3.3.2. Fv1 Restriction. Fv1 restriction was the ﬁrst system
for resistance to MLV to be described in mice [104]. Inbred
mouse strains carry the “n” allele, the “b” allele, or the “nr”
allele at the Fv1 locus. In turn, naturally occurring MLVs
may be N-tropic or B-tropic. Fv1n or Fv1nr mice are partially
resistant to B-tropic MLVs, while the Fv1b locus encodes
partial resistance to N-tropic MLVs (Fv1nr mice are resistant
to some N-tropic MLVs as well as B-tropic MLVs). Passage
of an MLV in the restrictive host may ultimately lead to the
selection of a viral variant that has lost its sensitivity to Fv1
restriction; these laboratory isolates, such as Moloney MLV,
are termed NB-tropic. XMRV is unique in that it is restricted
by both Fv1n and Fv1b [105].
Despite many years of investigation, the mechanism of
Fv1 restriction is still not well understood. The Fv1 gene
p r o d u c ts e e m st ob eas o m e w h a td e g e n e r a t er e t r o v i r a lG a g
protein [106]. Genetic data indicate that it binds to a speciﬁc
site in the N-terminal domain of CA in the mature core of
the incoming virus particle. This interaction blocks infection
at a point between reverse transcription and integration
of the viral DNA. The Fv1 protein is present in cells at
extremely low levels [107]; in fact, restriction can be blocked
or “abrogated” by infection with a single particle of the
restricted type [108]. Particles which have been inactivated
by heat or gamma irradiation can retain the ability to
abrogate Fv1 restriction [109].
BiochemicalanalysisoftheFv1restrictionmachineryhas
proven extremely diﬃcult, but it appears that the ability of
the Fv1 protein to multimerize [110] is an essential element
inrestriction[111].ThespeciﬁcbindingoftheproteintoCA
protein of the restricted type seems to occur only when the
mature CA is in a lattice, as in the viral core; this binding was
recently demonstrated, for the ﬁrst time, using CA protein
arrayed on lipid nanotubes [112].
While the Fv1 restriction system is, as far as is known,
found only in mouse cells, human cells possess a somewhat
analogousrestrictionsystemeﬀectedbytheTRIM5αprotein.
TRIM5α was discovered by virtue of its ability to restrict
HIV-1, but it is also active against some MLVs; remarkably,
like the Fv1 gene product, it distinguishes between N-tropic
and B-tropic MLVs [113].
3.3.3. APOBEC3 Restriction. All placental mammals have at
least one member of the APOBEC3 gene family; humans
and chimpanzees have seven APOBEC3 genes [114, 115].
APOBEC3 proteins can be incorporated into retrovirus par-
ticles, and they interfere with viral replication during reverseAdvances in Virology 9
transcription when the APOBEC3-bearing virus particle
infects a new host cell. APOBEC3s are cytidine deaminases
with one or two zinc-coordinating motifs that are instru-
mental in the restriction of viral replication. It seems likely
that the primary function of APOBEC3s is protection of the
mammalianhostagainstpathogens(orintracellularparasites
such as retrotransposons): mice lacking mouse APOBEC3
(mA3) survive and reproduce normally but are very sensitive
to retrovirus infection [116, 117].
One way in which APOBEC3 proteins inactivate retro-
viruses is by hypermutation. By deaminating deoxycytidine
to deoxyuridine in minus-strand DNA during the synthesis
of viral DNA, they bring about a G to A change in the plus-
strand. Many susceptible viruses have been shown to incur
very high levels of G to A mutation as a result of APOBEC3
action. However, it is now clear that APOBEC3 proteins act
onretrovirusesin other waysaswell.For example, thedegree
ofinactivationofHIV-1byhumanAPOBEC3G(hA3G)does
not necessarily correlate with the level of G to A mutation
(reviewedin [118]),and hA3Ghasbeen showntoaﬀectboth
the synthesis and integration of HIV-1 viral DNA [119].
There are two isoforms of mA3, containing or lacking
exon 5. Most studies on mA3 have used the form lacking the
e x o n .M L V ss h o wd r a m a t i cd i ﬀerences in their sensitivity to
this mA3: both XMRV and AKV (the endogenous ecotropic
MLV in AKR mice, a mouse line bred for high leukemia
incidence) are far more sensitive to inactivation by mA3
than Moloney MLV (which was selected for rapid growth
and leukemogenicity by passage in mice over a period of
years) [105, 120–122]. Moreover, when DNA of XMRV or
AKV is synthesized in the presence of mA3, it contains
large numbers of G to A mutations [120, 121], but these
mutations are not detectably induced in Moloney MLV
by mA3 [100, 123]. Presumably, the creation of the AKR
mouse strain entailed the selection of mice that provide
a maximally permissive environment for AKV, and thus,
this virus has not faced selective pressure leading to mA3
resistance. In contrast, selection during passage of Moloney
MLV has led to partial resistance to inactivation by mA3,
and apparently complete resistance to the hypermutational
eﬀects of mA3. The mechanisms underlying these resistance
phenomena are unknown. It should be noted that in HIV-1,
one of the “accessory proteins”, that is, Vif, is responsible for
viral resistance to hA3G. Vif functions by binding to hA3G
and inducing its proteasomal degradation. However, as
emphasized above, MLVs do not encode accessory proteins,
and the resistance of Moloney MLV to mA3 must reside in its
Gag, Pol, and/or Env protein. As mA3 is packaged eﬃciently
in Moloney MLV particles [100, 123], the resistance does not
depend upon exclusion of mA3 from the virus.
The biology of MLV restriction by the mA3 containing
e x o n5i ss o m e w h a td i ﬀerent from the foregoing: mA3
protein containing this exon can be cleaved by MLV PR,
leading to the inactivation of this mA3 within MLV particles
[124].
3.3.4. Restriction by Tetherin. Recently, yet another antiviral
restriction system has been discovered, mediated by the
Virion
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Figure 7: Hypothetical mechanism of restriction by tetherin. The
cellular restriction factor tetherin can act as a bridge between two
membranes. Tetherin contains a transmembrane domain at its N-
terminus and is anchored to a membrane by a glycophosphatidyl
linkage at its C-terminus. It also dimerizes due to a parallel coiled-
coil structure between the termini of the protein. Anchorage to
membranes at both ends apparently enables tetherin to “trap” virus
particles, preventing their escape from the virus-producing cell. It
is not known which end of the protein is embedded in the cellular
membrane and which in the viral membrane. (Figure reproduced
with permission from [22].)
host protein “tetherin” (also known as CD317, BST2, or
HM1.24) [125]. Tetherin is a membrane protein with a very
unusual topology: it has a cytoplasmic N-terminus, followed
by a transmembrane helix, an extended ectodomain, and
a C-terminus associated with the plasma membrane by a
glycophosphatidyl inositol linkage. Tetherin dimerizes via
the ectodomain, which forms a coiled coil ∼90 ˚ Al o n g .T h e
presence of membrane anchors at both ends of the molecule
evidently gives it the ability to physically link released virus
particles to the surface of the virus-producing cell, eﬀectively
preventing their escape into the surrounding medium (see
Figure 7)[ 22].
Tetherins inhibit the release of all retroviruses tested,
and also of ﬁloviruses such as Ebola, arenaviruses such as
Lassa,andherpesvirusessuchasKaposi’ssarcoma-associated
herpesvirus. They are constitutively expressed on some cell
surfaces and are inducible by type I interferon in others.
Mouse tetherin has been shown to inhibit the replication
of MLV [126]. While lentiviruses have several alternative
countermeasures against tetherins, including the HIV-1
accessory protein Vpu (reviewed in [127]), no resistance
mechanisms in MLVs have yet been described.
4. Concluding Remarks
It is clear that MLVs have provided an extraordinary wealth
of information about retroviruses, both as physical objects10 Advances in Virology
and as living organisms. They (and other gammaretro-
viruses, such as gibbon ape leukemia virus) are now being
developed as vectors for gene therapy. As has been indicated
throughout this paper, the contrasts with other retroviruses
such as HIV-1 help to illustrate the range of possibilities
by which viruses solve common problems. Finally, as with
all viruses, MLVs provide a window into the “black box”,
an unparalleled opportunity to learn about the cells and
organisms that they infect. Indeed, many cellular proteins
havebeenshowntoparticipateinMLVreplication;whilethis
large topic is beyond the scope of this paper, it is the focus of
a fascinating review by Goﬀ [128].
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